I-131 CONTAMINATION FROM THYROID-CANCER PATIENTS

被引:0
|
作者
IBIS, E [1 ]
WILSON, CR [1 ]
COLLIER, BD [1 ]
AKANSEL, G [1 ]
ISITMAN, AT [1 ]
YOSS, RG [1 ]
机构
[1] MILWAUKEE CTY MED CTR,RADIAT SAFETY PROGRAM OFF,MILWAUKEE,WI
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
High-dose radioactive iodine therapy using I-131 is the treatment of choice for patients with thyroid cancer following thyroidectomy. Because of the large amount of activity which is excreted during hospitalization, contamination hazard from I-131 excretion via perspiration, saliva, breath and urine may arise. In eight patients treated with doses of I-131 ranging from 3.7 to 14.8 GBq (1 00-400 mCi), activity levels were measured in room air, from room surfaces, the toilet, the patients' exhaled breath, skin, saliva and toothbrushes, and the gloves used by medical staff. Thyroid bioassays were also performed on medical staff personnel caring for these patients both before and two days after administration of the treatment dose. Removable activity from the skin was positively correlated with treatment dose and reached a maximum at 24 hr post-therapy. Removable activity from room surfaces exceeded the level of contamination which requires clean-up in a restricted area during the patient's hospitalization. Thyroid bioassays on medical staff showed no significant uptake 2 days after treatment. The relatively high activities present in the saliva, urine and on the skin of these patients emphasizes the need for all individuals coming in contact with these patients to be made aware of the contamination hazard present.
引用
收藏
页码:2110 / 2115
页数:6
相关论文
共 50 条
  • [1] THYROID-CANCER - I-131 AND FERTILITY
    COUETTE, JE
    VAN, HL
    SWITSERS, O
    BRUNE, D
    LEMOUEL, M
    ROBILLARD, J
    JOURNAL DE BIOPHYSIQUE ET DE BIOMECANIQUE, 1987, 11 (03): : 134 - 134
  • [2] CIRCULATING I-131 THYROXINE AND THYROID-CANCER
    HAYS, MT
    MCDOUGALL, IR
    THYROID, 1994, 4 (02) : 195 - 198
  • [3] THYROID-CANCER AFTER I-131 TREATMENT
    BODANSKY, HJ
    LANCET, 1986, 2 (8509): : 755 - 756
  • [4] OPTIMIZATION OF I-131 SCAN DOSE IN PATIENTS WITH THYROID-CANCER
    WAXMAN, A
    RAMANNA, L
    CHAPMAN, N
    BRACHMAN, M
    TANASESCU, D
    BERMAN, D
    CATZ, B
    BRAUNSTEIN, G
    JOURNAL OF NUCLEAR MEDICINE, 1980, 21 (06) : P30 - P30
  • [5] I-131 NECK UPTAKE QUANTIFICATION IN PATIENTS WITH RESIDUAL THYROID-CANCER
    CHOPRA, S
    WASTIE, ML
    UBHI, CS
    CHAN, S
    VINCENT, RM
    PERKINS, AC
    PRZESLAK, A
    BRITISH JOURNAL OF SURGERY, 1995, 82 (10) : 1431 - 1431
  • [6] I-131 THERAPY OF THYROID-CANCER - EXTENSIVE CONTAMINATION OF THE HOSPITAL ROOM IN A PATIENT WITH TRACHEOSTOMY
    KAPPES, RS
    SARKAR, SD
    HAREL, G
    STRASHUN, AM
    DUNN, EK
    SCHUSSLER, GC
    JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (12) : 2053 - 2054
  • [7] MEASUREMENT OF IODINE BEFORE I-131 IN THYROID-CANCER
    REGALBUTO, C
    GULLO, D
    VIGNERI, R
    PEZZINO, V
    LANCET, 1994, 344 (8935): : 1501 - 1502
  • [8] THYROID CONTAMINATION FROM AIRBORNE I-131
    CAREY, JE
    SWANSON, DP
    JOURNAL OF NUCLEAR MEDICINE, 1979, 20 (04) : 362 - 362
  • [9] LEUKEMIA AFTER I-131 TREATMENT OF THYROID-CANCER - COMMENTS
    LARSSON, LG
    ACTA ONCOLOGICA, 1992, 31 (01) : 65 - 65
  • [10] USE OF I-131 IN THE DIAGNOSIS AND TREATMENT OF METASTATIC THYROID-CANCER
    SHACKLETON, MO
    ADAMS, BK
    ABRATT, RP
    SOUTH AFRICAN JOURNAL OF SCIENCE, 1987, 83 (09) : 573 - 573